|1.||Sasano, Hironobu: 15 articles (06/2010 - 01/2002)|
|2.||Suzuki, Takashi: 15 articles (06/2010 - 01/2002)|
|3.||Moriya, Takuya: 11 articles (06/2010 - 01/2002)|
|4.||Miki, Yasuhiro: 7 articles (06/2010 - 04/2007)|
|5.||Poirier, Donald: 7 articles (04/2010 - 11/2002)|
|6.||Ohuchi, Noriaki: 6 articles (06/2010 - 01/2002)|
|7.||Lin, Sheng-Xiang: 5 articles (01/2012 - 11/2002)|
|8.||Ishida, Takanori: 4 articles (06/2010 - 01/2002)|
|9.||Hirakawa, Hisashi: 4 articles (06/2010 - 04/2007)|
|10.||Stål, Olle: 4 articles (03/2010 - 08/2006)|
|1.||Breast Neoplasms (Breast Cancer)
01/01/2012 - "17beta-hydroxysteroid dehydrogenase type 1 modulates breast cancer protein profile and impacts cell migration."
03/01/2009 - "17HSD1 and 17HSD2 are the family members known to be of main importance in breast cancer. "
12/01/2008 - "Expression of 17beta-hydroxysteroid dehydrogenase type 2 and type 5 in breast cancer and adjacent non-malignant tissue: a correlation to clinicopathological parameters."
03/27/2006 - "The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer."
07/01/2005 - "Selective insensitivity of ZR-75-1 human breast cancer cells to 2-methoxyestradiol: evidence for type II 17beta-hydroxysteroid dehydrogenase as the underlying cause."
02/15/2009 - "17Beta-hydroxysteroid dehydrogenase type 12 in human breast carcinoma: a prognostic factor via potential regulation of fatty acid synthesis."
02/01/2000 - "17Beta-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters."
01/01/2010 - "Suppressed expression of type 2 3alpha/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma."
03/01/2005 - "Several studies have previously demonstrated the expression of androgen-producing enzymes such as 5alpha-reductase types 1 and 2, and 17beta-hydroxysteroid dehydrogenase type 5 (17beta-HSD5), in human prostate carcinoma cells. "
06/01/2010 - "Concentration of a potent androgen, 5alpha-dihydrotestosterone (DHT), was significantly higher in breast carcinoma tissue than in plasma, and DHT is considered to be locally produced from circulating androstenedione by 17beta-hydroxysteroid dehydrogenase type 5 and 5alpha-reductase. "
04/01/2007 - "Expression of 17beta-hydroxysteroid dehydrogenase type 2 in pelvic endometriosis."
12/01/1998 - "Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17beta-estradiol."
04/01/2004 - "The aim of this study was to demonstrate the temporal and spatial expression of estrogen receptor (ER), 17beta-hydroxysteroid dehydrogenase (17beta-HSD) in uterine endometria and the endometrial-myometrial interface (EMI) of adenomyosis and the effects of estrogen activity-related molecules on the occurrence of adenomyosis. "
12/01/1998 - "In this study, we initially demonstrated by Northern blotting transcripts of the reductive 17beta-hydroxysteroid dehydrogenase (17betaHSD) type 1, which catalyzes the conversion of estrone to 17beta-estradiol, in both eutopic endometrium and endometriosis. "
04/01/2007 - "Lack of expression or a deficiency of 17beta-hydroxysteroid dehydrogenase type 2 (17beta-HSD2), a key enzyme in estradiol inactivation, could be involved in the pathophysiology of endometriosis. "
|4.||Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
03/28/1996 - "In the present study, expressions of 17beta-hydroxysteroid dehydrogenase (17HSD) types 1, 2, and 3, 5alpha-reductase type 2 and human androgen receptor mRNAs were determined in 12 benign prostatic hyperplasia and 17 prostatic carcinoma specimens. "
08/01/2006 - "17beta-Hydroxysteroid dehydrogenase (17beta-HSD) types 1, 2, 4, 7, and 12, as well as aromatase mRNA and protein expressions, were studied in benign prostatic hyperplasia (BPH) specimens using in situ hybridization and immunohistochemistry. "
03/16/1998 - "The aim of this study on testosterone (T) metabolism in benign prostatic hyperplasia (BPH) and prostatic cancer was to compare the formation of metabolites in freshly isolated epithelial cells and in cells of long-term cultures (2 passages) and to identify the 5alpha-reductase (5alpha-R) and 17beta-hydroxysteroid dehydrogenase (17beta-HSD) isoforms responsible for metabolite formation. "
|5.||Prostatic Neoplasms (Prostate Cancer)
01/01/2009 - "17beta-hydroxysteroid dehydrogenase type 11 (Pan1b) expression in human prostate cancer."
02/01/2005 - "We analyzed single nucleotide polymorphisms (SNP) in the 17beta-hydroxysteroid dehydrogenase (HSD17B) genes, which are involved in the metabolism of EMP, to predict the risk of EMP side-effects in prostate cancer patients. "
10/01/2002 - "Differential expression of 17beta-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues."
01/01/2001 - "Inhibitors of human and rat testes microsomal 17beta-hydroxysteroid dehydrogenase (17beta-HSD) as potential agents for prostatic cancer."
11/01/1997 - "Expression of different 17beta-hydroxysteroid dehydrogenase types and their activities in human prostate cancer cells."
|6.||Steryl-Sulfatase (Steroid Sulfatase)